title: Comments to: Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.
authors.affiliation: Department of Ophthalmology, University of Medicine Cluj-Napoca - Romania.
authors.forename: Dan
authors.initials: D
authors.lastname: Călugăru
authors.affiliation: Department of Ophthalmology, University of Medicine Cluj-Napoca - Romania.
authors.forename: Mihai
authors.initials: M
authors.lastname: Călugăru
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab